Haemonetics (HAE) investor relations material

Strategic achievements and financial performance

• Achieved double-digit revenue growth excluding CSL, high teens EPS growth, and added 660 basis points to operating income margin, generating nearly $700 million in free cash flow over four years.

• Built a foundation for durable growth, with a focus on three core products: NexSys, TEG, and VASCADE, which account for 85% of revenue and are primarily U.S.-based.

• Plasma business saw a trifecta of share gains, innovation-based pricing, and double-digit collection volume growth, especially in Europe and later in the U.S.

• Guidance for plasma collection volume growth remains prudent at 0%-2%, with expectations for continued positive trends into FY 2027.

• Margin expansion continues, with plasma gross margins rising from 43% to mid-50%s, and further gains expected from Persona PLUS.

Market dynamics and innovation

• Plasma market demand for IG-based therapy remains strong, with no obstacles to ongoing growth; innovation in yield and speed, plus integrated software and analytics, drive competitive advantage.

• Share in plasma never dropped below 50% despite industry transitions, with aspirations to return to 70%+ share based on technology and service superiority.

• Ongoing innovation pipeline includes incremental software and AI-enabled analytics, with steady product enhancements planned.

• Plasma's best days are seen ahead, driven by rising IG demand for immune deficiency and cancer therapy, and new patient starts in autoimmune therapies.

Vascular closure and hospital business outlook

• Vascular closure declined 9% in FY 2026 but showed sequential growth in Q4, with confidence in IVT contributing to mid-single-digit growth in FY 2027.

• Commercial team improvements, label expansion for MVP XL, and acquisition of Vivasure strengthen the value proposition and support growth in IDN and ASC channels.

• Market stabilization expected as PFA adoption plateaus, with access site growth rate projected to double in FY 2027.

• Expanded indications and clinical data for MVP XL and VASCADE position products well for ASC and IDN adoption, especially in leading states.

• PerQseal Elite acquisition adds a sutureless, bioabsorbable large-bore closure product, targeting a $300 million addressable market with workflow efficiencies.